The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AXOGEN INC COM 05463X106 20,171 1,276,645 SH   SOLE   1,276,645 0 0
BIOVENTUS COM CL A 09075A108 171,289 12,096,702 SH   SOLE   12,096,702 0 0
CATALYST BIOSCIENCES INC COM NEW 14888D208 323 78,622 SH   SOLE   78,622 0 0
EYEPOINT PHARMACEUTICALS INC COM NEW 30233G209 43,669 4,190,921 SH   SOLE   4,190,921 0 0
MEDICINOVA INC COM NEW 58468P206 4,192 1,105,941 SH   SOLE   1,105,941 0 0
MIMEDX GROUP, INC. COM 602496101 141,662 23,376,623 SH   SOLE   23,376,623 0 0
REVANCE THERAPEUTICS INC COM 761330109 13,166 472,590 SH   SOLE   472,590 0 0
TELA BIO, INC. COM 872381108 25,052 1,833,989 SH   SOLE   1,833,989 0 0
VENUS CONCEPT, INC. COM 92332W105 31,169 12,417,856 SH   SOLE   12,417,856 0 0